

Part I Protein Kinase Inhibitors

1	Imatinib Mesylate	3
	Cornelius F. Waller	
1.1	Introduction.	3
1.2	Chemical Structure	5
1.3	Clinical Pharmacology	6
1.4	Drug Targets	6
1.5	Preclinical Studies	6
1.6	Clinical Data in CML	8
1.6.1	Phase I Trials	8
1.6.2	Phase II Studies.	8
1.6.3	Phase III Study (IRIS-Trial)	9
1.6.4	Side Effects/Toxicity.	10
1.7	Disease Progression and Imatinib Resistance.	11
1.8	Treatment Recommendations for the Use of Imatinib in Chronic Phase CML	14
1.9	Imatinib in Combination with Other Drugs	15
1.10	Imatinib – Other Targets	15
1.11	Conclusion and Future Perspectives.	16
	References.	17
2	Erlotinib	21
	M. Steins, M. Thomas, and M. Geißler	
2.1	Introduction.	21
2.2	Mechanism of Action	22
2.3	Non-Small Cell Lung Cancer	22
2.4	Pancreatic Adenocarcinoma	24
2.5	Hepatocellular Carcinoma	27
2.6	Other Tumour Entities	28
	References.	28

3	Axitinib (AG-013736)	33
	Ronan Joseph Kelly and Olivier Rixe	
3.1	Introduction.	33
3.2	Structure of Molecule	34
3.3	Preclinical Data.	34
3.3.1	Bioavailability in Humans	36
3.4	Phase II Studies.	36
3.4.1	Axitinib in Renal Cell Carcinoma	36
3.4.2	Axitinib in Pancreatic Cancer.	37
3.4.3	Axitinib in Metastatic Breast Cancer	38
3.4.4	Axitinib in Thyroid Cancer.	38
3.4.5	Axitinib in Other Solid Tumors	39
3.5	Phase III Studies	39
3.6	Toxicity.	40
3.7	Drug Interactions	41
3.8	Future	42
	References.	42
4	Lapatinib	45
	Tanja Schneider-Merck and Martin Trepel	
4.1	Introduction.	45
4.1.1	The Epidermal Growth Factor Receptor Family of Tyrosine Kinases	45
4.1.2	Human Epidermal Growth Factor Receptors and Breast Cancer.	47
4.2	Structure and Mechanism of Action.	47
4.3	Clinical Data.	49
4.3.1	Pharmacology.	49
4.3.2	Results from Clinical Trials	49
4.4	Conclusion and Future Perspectives.	54
	References.	55
5	Sorafenib	61
	Jens Hasskarl	
5.1	Introduction.	61
5.2	Structure and Mechanism of Action.	62
5.3	Clinical Data.	64
5.3.1	Phase I.	64
5.3.2	Sorafenib in the Treatment of Renal Cell Cancer (RCC).	64
5.3.3	Sorafenib in the Treatment of Lung Cancer	66
5.3.4	Sorafenib in the Treatment of Hepatocellular Cancer (HCC)	66
5.3.5	Sorafenib in the Treatment of Breast Cancer	66
5.3.6	Sorafenib in the Treatment of Malignant Melanoma	66
5.3.7	Sorafenib in the Treatment of Prostate Cancer.	67

5.3.8	Sorafenib in the Treatment of Head and Neck Cancer	67
5.3.9	Sorafenib in the Treatment of Ovarian Cancer	67
5.3.10	Sorafenib in the Treatment of Brain Tumors	67
5.3.11	Sorafenib in the Treatment of Thyroid Cancer	67
5.3.12	Sorafenib in the Treatment of Hematologic Diseases	67
5.4	Conclusion and Future Perspectives	68
	References	68
6	Sunitinib	71
	Daniel Y. C. Heng and Christian Kollmannsberger	
6.1	Introduction	71
6.2	Sunitinib	71
6.3	Renal Cell Carcinoma	72
6.3.1	Targets for Renal Cell Carcinoma	72
6.3.2	Phase II/III Studies in Metastatic RCC	74
6.4	Gastrointestinal Stromal Tumors	75
6.4.1	Targets for Gastrointestinal Stromal Tumors	75
6.4.2	GIST Clinical Trials	75
6.4.3	Side Effects	76
6.4.4	Drug Interactions	78
6.4.5	Activity in Other Tumor Sites and Ongoing Research	78
6.5	Conclusion	79
	References	79
7	Dasatinib	83
	Markus Lindauer and Andreas Hochhaus	
7.1	Introduction	83
7.2	Structure and Mechanism of Action	85
7.2.1	Inhibition of ABL	86
7.2.2	Inhibition of SRC	87
7.2.3	Inhibition of c-KIT	87
7.2.4	Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR)- α and β Tyrosine Kinases	88
7.2.5	Inhibition of Ephrin Receptor Tyrosine Kinases	88
7.2.6	Additional Effects	88
7.3	Clinical Data	88
7.3.1	Pharmacokinetic Profile	88
7.3.2	Clinical Studies with Dasatinib in CML and Other Diseases	89
7.3.3	CML and Ph ⁺ ALL – Overview	89
7.3.4	Dasatinib and Other Diseases	95
7.3.5	Safety and Tolerability	96
7.4	Conclusion and Further Perspectives	98
	References	99

8	Nilotinib	103
	Alfonso Quintás-Cardama, Theo Daniel Kim, Vince Cataldo, and Philipp le Coutre	
8.1	Background	103
8.2	Preclinical and Pharmacokinetic Data	104
8.2.1	Pharmacological Design	104
8.2.2	Drug Targets	104
8.2.3	Preclinical Activity	104
8.2.4	Pharmacokinetics and Metabolism	105
8.3	Clinical Efficacy	105
8.3.1	Nilotinib Phase I Study	106
8.3.2	Nilotinib After Imatinib Failure	106
8.3.3	Nilotinib First-Line Therapy	108
8.3.4	Nilotinib After Dasatinib Failure	108
8.3.5	Toxicity	109
8.3.6	Resistance to Nilotinib	112
8.4	Outlook	113
8.5	Conclusion	114
	References	114
9	Bosutinib	119
	Gunhild Keller, Philippe Schafhausen, and Tim H. Brümmendorf	
9.1	Chemical Structure	119
9.2	Mechanism of Action	119
9.2.1	SRC Kinase Inhibition	120
9.2.2	Abl and bcr-abl Inhibition	120
9.3	Bosutinib in Chronic Myeloid Leukaemia (CML)	121
9.3.1	Preclinical Data	121
9.3.2	Clinical Trials	121
9.4	Bosutinib in Solid Tumours	124
9.4.1	Preclinical Data	124
9.4.2	Clinical Trials	125
9.5	Conclusion and Future Directions	125
	References	126
Part II Epigenetic Modifiers		
10	Decitabine	131
	Michael Daskalakis, Nadja Blagitko-Dorfs, and Björn Hackanson	
10.1	Introduction	131
10.2	Structure and Mechanism of Action	132
10.3	Studies of Single-Agent Decitabine in MDS and Acute Leukemias	133
10.4	Combination Treatment in AML, MDS, and Other Diseases.	135

10.5	Decitabine as a Preparative Agent in Allogeneic Stem Cell Transplantation	140
10.6	Immunomodulation with Decitabine	142
10.7	Decitabine Treatment in Other Diseases	143
10.7.1	Activity of Decitabine in Patients with Acute Lymphoblastic Leukemia	143
10.7.2	Activity of Decitabine in Patients with Chronic Myeloid Leukemia	144
10.7.3	Activity of Decitabine in Patients with Idiopathic Myelofibrosis (IMF)	145
10.7.4	Clinical Effects of Decitabine in Severe β -Thalassemia and Sickle Cell Disease	145
10.7.5	Efficacy of Decitabine in Patients with Solid Tumors	146
10.8	Conclusion and Future Perspectives	148
	References	149
11	5-Azacytidine/Azacitidine	159
	Antonia Müller and Mareike Florek	
11.1	Introduction: 5-Azacytidine – Novel or Almost Historic?	159
11.2	Agent	160
11.2.1	Chemical Structure	160
11.2.2	Mode of Action	160
11.3	Pharmacology	161
11.3.1	Route of Administration and Dosage	161
11.3.2	Bioavailability, Half-Life, Elimination, Drug–Drug Interactions	162
11.3.3	Safety, Side Effects, and Contraindications	162
11.4	Clinical Use of 5-Azacytidine	164
11.4.1	Early Studies	164
11.4.2	5-Azacytidine in Myelodysplastic Syndromes (MDS)	164
11.4.3	New Therapeutic Approaches	166
11.5	Future Perspective, Experimental Studies, and Conclusion	166
	References	167
 Part III Cell Cycle Inhibitors		
12	Bortezomib	173
	Hermann Einsele	
12.1	Mode of Action	173
12.2	Antitumor Effects	175
12.3	Clinical Application of Proteasome Inhibitors	176
12.4	Bortezomib	177
12.5	Bortezomib-Based Combination Therapy for Multiple Myeloma	178

12.6	Treatment Options for Patients Eligible for Transplant	179
12.7	Next Generation Proteasome Inhibitors	179
	References.	180
13	Temsirolimus	189
	Christian Stock, Massimo Zaccagnini, Michael Schulze, Dogu Teber, and Jens J. Rassweiler	
13.1	Introduction.	189
13.2	Development.	190
13.3	Structure and mechanism of action.	190
13.4	Clinical Data.	192
13.5	Safety and Efficacy.	192
13.6	Side Effects.	193
13.7	Conclusion and Future Perspectives.	194
	References.	195
14	Danuserib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor	199
	Artur Gontarewicz and Tim H. Brümmendorf	
14.1	Introduction.	199
14.2	Structure, Localization, and Functions.	200
14.3	Aurora Kinases and Cancer	201
14.4	Inhibitors.	202
14.5	Danuserib (formerly PHA-739358).	204
14.6	Conclusion	208
	References.	209
15	BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)	215
	R. Wäsch, J. Hasskarl, D. Schnerch, and M. Lübbert	
15.1	Introduction.	215
15.2	Structure and Mechanism of Action.	217
15.3	Clinical Data.	217
15.4	Conclusion and Future Perspectives.	218
	References.	218
Part IV Other Novel Agents		
16	Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy	221
	Alexander Röth, Calvin B. Harley, and Gabriela M. Baerlocher	
16.1	Introduction.	221
16.2	Telomerase-Based Approaches of Cancer Treatment.	224
16.3	Telomerase Inhibition.	224
16.4	Structure of Imetelstat and Mechanism of Action	224

16.5	Preclinical and Clinical Data of Imetelstat	225
16.6	Conclusion and Future Prospects	229
	References.	229
17	GDC-0449 - Targeting the Hedgehog Signaling Pathway	235
	Christine Dierks	
17.1	Introduction.	235
17.2	Structure and Mechanism of Action.	236
17.3	Clinical Data.	236
17.4	Conclusion and Future Perspectives.	237
	References.	237